Arkolith/Insider Trading/SPRY/Form 4

Karas Eric

Chief Commercial OfficerARS Pharmaceuticals, Inc. (SPRY) · full profile →Form 4 · filed Jan 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2026Grant(A)240K—$0240K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001951287-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML